Circle8 Group (CIRC) vs 10x Genomics (TXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
10x Genomics (TXG) has outperformed Circle8 Group (CIRC) over the past year, gaining 556.0% versus a loss of 84.7%. Over five years, TXG leads with a -50.0% price change compared with -99.7% for CIRC. 10x Genomics is the larger company by market cap ($9.92 billion vs $52.6 million), about 188.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CIRC | TXG |
|---|---|---|
| Share price | $0.46 | $76.10 |
| Market cap | $52.63M | $9.92B |
| 1-day change | -7.26% | -5.65% |
| YTD return | -65.41% | +366.58% |
| 1-year return | -84.67% | +556.03% |
| 5-year return | -99.67% | -50.02% |
| Forward P/E | — | 992.57 |
| EPS (TTM) | $-2.14 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $642.82M |
| Revenue growth (YoY) | — | +5.25% |
| Net income (latest FY) | — | $-43.54M |
| Gross margin | — | 69.05% |
| Operating margin | — | -9.49% |
| Net margin | — | -6.77% |
| 52-week high | $4.56 | $102.81 |
| 52-week low | $0.313 | $11.16 |
| Distance from 52-week high | -89.91% | -25.98% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | -13.27% |
| Average volume | 2.78M | 3.15M |
| Shares outstanding | 114.41M | 120.21M |
| Employees | — | 1,178 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- 10x Genomics is about 188.4 times larger than Circle8 Group by market value ($9.92B vs $52.63M).
- TXG has outperformed CIRC by 640.7 percentage points over the past year.
About 10x Genomics
TXG stock →10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
Industrials · Biotechnology: Laboratory Analytical Instruments · 1,178 employees
CIRC vs TXG FAQ
Which is bigger, Circle8 Group or 10x Genomics?
10x Genomics (TXG) is larger, with a market capitalization of $9.92B compared with $52.63M for Circle8 Group (CIRC).
Which stock has performed better over the past year, CIRC or TXG?
TXG returned +556.03% over the past 12 months, compared with -84.67% for CIRC (price return, excluding dividends). Past performance does not predict future results.
Are Circle8 Group and 10x Genomics in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.